Patents by Inventor Joanne L. Flynn

Joanne L. Flynn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treating bacterial infections
    Patent number: 11865168
    Abstract: Provided herein are compositions and methods for therapeutic and/or prophylactic treatment of an intracellular bacterial infection in a subject in need thereof, comprising one or more modulating agents, wherein the one or more modulating agents increase expression of IFN?, IL-2, TNF, and/or IL-17 in systemic and/or lung T cells. In some embodiments, the increase of expression of IFN?, IL-2, TNF, and/or IL-17 occurs in lung T cells. The lung T cells can be lung resident T cells or systemic T cells that are recruited to the lung. In some embodiments, the T cells are CD4+ and/or CD8+ T cells. In some embodiments, the intracellular bacterial infection is a Mycobacterium tuberculosis (MTB) infection.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: January 9, 2024
    Assignees: Massachusetts Institute of Technology, The United States of America, as represented by The Secretary, Department of Health & Human Services, University of Pittsburgh—Of The Commonwealth System of Higher Education
    Inventors: Alexander K. Shalek, Travis Hughes, Marc H. Wadsworth, Robert Seder, Mario Roederer, Joanne L. Flynn, Patricia Darrah
  • COMPOSITIONS AND METHODS FOR TREATING BACTERIAL INFECTIONS
    Publication number: 20210213126
    Abstract: Provided herein are compositions and methods for therapeutic and/or prophylactic treatment of an intracellular bacterial infection in a subject in need thereof, comprising one or more modulating agents, wherein the one or more modulating agents increase expression of IFN?, IL-2, TNF, and/or IL-17 in systemic and/or lung T cells. In some embodiments, the increase of expression of IFN?, IL-2, TNF, and/or IL-17 occurs in lung T cells. The lung T cells can be lung resident T cells or systemic T cells that are recruited to the lung. In some embodiments, the T cells are CD4+ and/or CD8+ T cells. In some embodiments, the intracellular bacterial infection is a Mycobacterium tuberculosis (MTB) infection.
    Type: Application
    Filed: December 30, 2020
    Publication date: July 15, 2021
    Inventors: Alexander K. Shalek, Travis Hughes, Marc H. Wadsworth, Robert Seder, Mario Roederer, Joanne L. Flynn, Patricia Darrah